The value of histopathology combined with CapitalBio Mycobacterium real-time polymerase chain reaction test for diagnosing spinal tuberculosis
- PMID: 37425306
- PMCID: PMC10326313
- DOI: 10.3389/fmed.2023.1173368
The value of histopathology combined with CapitalBio Mycobacterium real-time polymerase chain reaction test for diagnosing spinal tuberculosis
Abstract
Purpose: To evaluate the diagnostic efficacy of CapitalBio Mycobacterium real-time polymerase chain reaction assay (CapitalBio test) in spinal tuberculosis (STB). The value of histopathology combined with the CapitalBio test in diagnosing STB was also assessed.
Methods: We retrospectively analyzed the medical information of suspected STB. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) of histopathology, CapitalBio test, and histopathology combined with CapitalBio test were calculated to evaluate their diagnostic efficacy compared with a composite reference standard.
Results: A total of 222 suspected STB patients were included in the study. The sensitivity, specificity, PPV, NPV, and AUC of histopathology for STB were recorded to be 62.0, 98.0, 97.4, 68.3%, and 0.80, respectively. The sensitivity, specificity, PPV, NPV, and AUC of the CapitalBio test were 75.2, 98.0, 97.9, 76.7%, and 0.87, respectively, while that of histopathology combined with the CapitalBio test was 81.0, 96.0, 96.1, 80.8%, and 0.89, respectively.
Conclusion: Histopathology and CapitalBio test exhibited high accuracy and are recommended in diagnosing STB. Histopathology combined with the CapitalBio test might give the best efficacy in STB diagnosis.
Keywords: CapitalBio test; accuracy; histopathology; molecular test; spinal tuberculosis.
Copyright © 2023 Yao, Bu, Zhang and Zhang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




Similar articles
-
Comparison of the diagnostic efficacy of the CapitalBio Mycobacterium real-time polymerase chain reaction detection test and Xpert MTB/RIF in smear-negative pulmonary tuberculosis.Eur J Clin Microbiol Infect Dis. 2021 May;40(5):969-977. doi: 10.1007/s10096-020-04113-1. Epub 2020 Nov 26. Eur J Clin Microbiol Infect Dis. 2021. PMID: 33242168
-
Comparison of the Diagnostic Accuracy of Xpert MTB/RIF and CapitalBio Mycobacterium RT-PCR Detection Assay for Tuberculous Pericarditis.Infect Drug Resist. 2022 Apr 22;15:2127-2135. doi: 10.2147/IDR.S360064. eCollection 2022. Infect Drug Resist. 2022. PMID: 35498628 Free PMC article.
-
CapitalBio Mycobacterium real-time polymerase chain reaction detection test: Rapid diagnosis of Mycobacterium tuberculosis and nontuberculous mycobacterial infection.Int J Infect Dis. 2020 Sep;98:1-5. doi: 10.1016/j.ijid.2020.06.042. Epub 2020 Jun 14. Int J Infect Dis. 2020. PMID: 32553719
-
Enhancing the Accuracy of Peripheral Pulmonary Tuberculosis Diagnosis: A Comparative Evaluation of CapitalBioTM Mycobacterium Nucleic Acid Detection Test and Mycobacterium tuberculosis Isothermal RNA Amplification Assay Using Endobronchial Ultrasonography with Guide Sheath.Infect Drug Resist. 2024 Oct 25;17:4685-4693. doi: 10.2147/IDR.S476732. eCollection 2024. Infect Drug Resist. 2024. PMID: 39473911 Free PMC article.
-
Comparison of the Accuracy of Two Different Molecular Tests for the Diagnosis of Tuberculous Lymphadenitis Using Core Needle Biopsy Specimens: A Diagnostic Accuracy Study.Int J Gen Med. 2022 May 27;15:5237-5246. doi: 10.2147/IJGM.S367127. eCollection 2022. Int J Gen Med. 2022. PMID: 35655654 Free PMC article.
Cited by
-
Evaluation and Comparison of Laboratory Methods in Diagnosing Mycobacterium tuberculosis and Nontuberculous Mycobacteria in 3012 Sputum Samples.Clin Respir J. 2025 Mar;19(3):e70071. doi: 10.1111/crj.70071. Clin Respir J. 2025. PMID: 40087831 Free PMC article.
References
LinkOut - more resources
Full Text Sources